Sanofi's patent medicine was shortlisted and 50% of the price was cut

2013-06-05 source: which is the priority between daily economic news price and market? Recently, according to the notice on confirmation of shortlisted price for supplementary entry into primary medical institutions issued by drug purchasing center of Shaanxi medical institutions, the price of 75 mg * 7 of Plavix under Sanofi is 65.3 yuan This news caused a great uproar in the market, because the shortlisted price of 65.3 yuan was 47% lower than the bidding price of 119 yuan for non base drugs in 2011 Will Sanofi accept the bidding price? Yan Yunqing, director of communication and media of Sanofi Asia Group, didn't make a clear statement in response to the interview with the reporter of daily economic news He only said that the company has been informed of the notice and relevant prices, and is still in the process of communication What makes Sanofi "tangle" is that if Sanofi does not confirm the price, it means that Sanofi cannot enter the basic medical institutions in Shaanxi Province for sales Judging from this incident, price has become a problem for Sanofi to move to the grassroots level Sanofi's "dilemma" according to the regulations of Shaanxi medical institution procurement center, the price of varieties involved in the 2012 edition of national essential drug catalog supplement is determined according to the lowest price quoted by all enterprises from shortlisted to winning the bid If the relevant suppliers fail to confirm the price, they will not be able to enter the sales of basic medical institutions in Shaanxi Province This means that the price of 65.3 yuan is the lowest price quoted by all enterprises from shortlisted to winning the bid If Sanofi does not confirm the shortlisted price, it is equivalent to giving up the sale of the product in the basic medical structure of Shaanxi Province How will Sanofi choose? From the current response of Sanofi, it is still uncertain whether the company will accept such a price The reporter learned that Plavix is the original research drug of Sanofi, a French pharmaceutical giant According to some insiders, Plavix is the second best-selling drug in the world in terms of revenue, with sales of 3 billion yuan in China last year In May last year, the patent protection of Plavix expired A medical person told the daily economic news that Sanofi should not accept such a low price After all, Plavix only lost patent protection last year, but in fact, it has certain advantages If such a price can greatly reduce the profits of the product, Sanofi may not sacrifice profits From this incident, Sanofi is facing a big price problem when entering the grassroots On the one hand, if Sanofi accepts the price that is nearly half lower than before, it means that it has given up profits; on the other hand, if it gives up this opportunity, it will not be able to enter the basic drug market in Shaanxi Therefore, in many industry understandings, "price" has become a barrier for many multinational pharmaceutical enterprises to enter the primary medical market Take the initiative to cut prices and seize the market? Industry insiders believe that it is not wise to reduce the price to enter the base drug market when the patent medicine expires This time, it is also likely that Sanofi will take the initiative to reduce the price in exchange for the grassroots market "It's OK to reduce the price If the grass-roots doctors form the habit of using drugs, it's inevitable to give large amount But if habits have not been formed, the scale of large-scale will not be very large " Yuanru consults yuan Zehong and tells the reporter of the daily economic news Moreover, with the expiration of Plavix's patent protection in the U.S market in May last year, many enterprises joined the ranks of generic drugs In 2012, the State Food and Drug Administration approved more than 40 generic pharmaceutical enterprises of Plavix With the increase of imitation enterprises, the market share of Plavix is gradually shrinking in recent years In 2011, the share of Plavix in the domestic market of clopidogrel dropped to 73.31%, while the share of Tredegar produced by its competitor, xinlitai, rose to 26.69% "Entering the primary market is what Sanofi is doing, and this product is also within the scope If there is no price reduction, it is difficult to maintain the market share at a retail price 50% higher than that of the competitors, so It's like giving up the competition in the primary market " The aforementioned insiders told reporters that, therefore, the price is not excluded from Sanofi's initiative, hoping to occupy the market at a low price The reporter learned that at present, the main market share of multinational pharmaceutical enterprises is in the second and third level hospitals However, after the new version of the catalogue is issued, all regions need to stipulate the proportion of basic drugs used by medical institutions at all levels, so that the bid winning price of basic drugs bidding can be directly brought into the bidding of large hospitals, so that the same variety of the same manufacturer is the same price in the whole province Many people in the industry think that for drugs whose patents have expired, it may be a very good way to enter primary medical care What's more, if Sanofi enters the primary medical treatment this time, it may be a more fatal blow to competitors "Because Plavix has passed the patent period, Sanofi's acceptance of this price means Plavix will trample on domestic manufacturers to achieve unification." Yuan Zehong told the daily economic news